<DOC>
	<DOCNO>NCT00303082</DOCNO>
	<brief_summary>The trial intend evaluate efficacy specially design probiotic prevent premature birth relate neonatal morbidity associate intra-uterine infection . The tested probiotic efficacious decrease prevalence bacterial vaginosis . The study hypothesis early administration probiotic pregnant woman bacterial vaginosis prevent premature birth antibiotic activity modulation immune response infection .</brief_summary>
	<brief_title>Probiotics Prevention Premature Birth Neonatal Related Morbidity</brief_title>
	<detailed_description>The study design randomize placebo-controlled double-blind trial screen asymptomatic low risk pregnant woman without indication elective premature birth admit 20th week pregnancy ( Date LMP ultrasound ) prenatal care public service involve project city Rio de Janeiro . Relevant prognostic factor register : history premature birth , race low body index . After clinical screening follow screening process : 1. vaginal pH exam determine take swab roll glass slide touch pH stick . This procedure immediately exclude patient pH &lt; 4,5 next step ; 2 . The slides patient vaginal pH &gt; 4.4 , Gram stain interpret accord criterion Nugent et al order select patient BV intermediate Nugent score ( 4-10 ) . Patients Nugent score 4 exclude . Pregnant woman exclude step reassess every 4 week , new case BV/Intermediate score , next prenatal care visit , reach 19th week . BV/Intermediate patient randomize ( centralize block randomization process ) , sign informed consent , receive either probiotic placebo capsule twice day ( capsule probiotic shall contain &gt; 1 million bacillus 2 select strain lactobacillus : Lactobacillus rhamnosus GR1 Lactobacillus reuteri RC-14 ) . Women shall take capsule reach approximately 24th week gestation , minimum duration treatment 6 week ( woman randomize trial 20th week ) . Capsules maintain refrigerator throughout trial . Pregnant woman receive usual prenatal care institution , follow relate evidence-based municipal guideline . Vaginal pH Nugent score assess end treatment treatment group , assess change parameter partial result regard efficacy study probiotic . Randomized patient , whether compliant treatment regimen , follow assessment trial endpoint : spontaneous premature birth ( &lt; 37 , &lt; 35 , &lt; 32 week pregnancy ) relate neonatal event : early sepsis , bronchopulmonary dysplasia , periventricular leukomalacia necrotizing enterocolitis , besides death average hospital stay . Study personnel abstract information delivery neonatal record use pre-tested questionnaire . Definitions diagnostic method use identify condition similar recommend Vermont- Oxford Network , issue 2002 . The occurrence adverse event monitor specific questionnaire . The adherence treatment assess specific question pregnant woman count capsule contain bottle return prenatal care visit . Reasons non adherence , include occurrence adverse event , look order propitiate adherence whenever possible . Special attention devote avoid undesirable psychological effect derive eventual label woman high risk premature birth . Procedures assure concealment randomization blind pregnant woman ( identical placebo ) study personnel , include caretaker technician perform pH Nugent exam , describe protocol . In order add explanatory power present trial , regard mechanism action study probiotic , nest case-control study ( 1 case 3 control ) carry determine level select cytokine ( IL-1B , IL1-ra IL-6 ) vaginal fluid , treatment , occurrence TNF IL 6 ( 308 174 ) polymorphism , association , individually interaction , study endpoint ( case ) . Special vaginal swab ( cytokine ) oral sample ( polymorphism ) collect purpose process accordingly . Written inform consent also seek procedure . The trial approve Institutional Review Board send final approval National Review Board . ************************************************************ Sample size show efficacy study probiotic prevent premature birth less 35 32 week ( significance level 0.05 power 0.80 ) : _____________________________________________________________________ Considering : - use pH &lt; 4.5 cutoff point Nugent assessment result exclude around 40 % clinically pre-selected woman ( Hauth et al,2003 ) exclude small percentage woman NugentÂ´s Intermediate score related preterm birth , - non-adherence rate treatment regimens 5 % , - incidence placebo group premature birth le 35 week around 6 % ; - efficacy rate 50 % study main end-point ( premature birth ) , number estimate necessary randomization phase present trial , 1500 woman . To assess efficacy regard premature birth le 32 week , significance level power , correspond number nearly 3000 .</detailed_description>
	<mesh_term>Premature Birth</mesh_term>
	<mesh_term>Vaginal Diseases</mesh_term>
	<mesh_term>Bronchopulmonary Dysplasia</mesh_term>
	<mesh_term>Vaginosis , Bacterial</mesh_term>
	<mesh_term>Leukomalacia , Periventricular</mesh_term>
	<criteria>Asymptomatic pregnant woman indication elective preterm delivery , 20th week pregnancy major malformation present pregnancy cervical cerclage symptomatic vaginosis insulin dependent diabetes arterial hypertension Multiple gestation Antibiotic therapy present pregnancy Syphilis gonorrhea present pregnancy asthma require chronic intermittent therapy corticotherapy ( recent chronic ) perinatal hemolytic disease Systemic Erit . Lupus</criteria>
	<gender>Female</gender>
	<minimum_age>14 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2009</verification_date>
	<keyword>Probiotics</keyword>
	<keyword>Bacterial Vaginosis</keyword>
	<keyword>Premature birth</keyword>
	<keyword>Intra-uterine Infection</keyword>
	<keyword>Periventricular leukomalacia</keyword>
</DOC>